2 / 28
Background
●
Approximately 1/3 of NSCLC patients have stage III, locally advanced disease at diagnosis
●
SoC for patients with a good performance status and unresectable, stage III NSCLC is
platinum-based doublet chemotherapy, concurrent with radiotherapy
●
Median PFS with concurrent chemoradiation therapy (cCRT) is approximately 8–10 months (from
the start of cCRT) and only 15% are alive at 5 years
●
There have been no major advances in locally advanced NSCLC for several years
,
thus, there is
significant unmet need for novel therapeutic approaches to boost survival beyond cCRT
●
PACIFIC is the first randomized phase III study to evaluate immune checkpoint blockade in patients
with stage III, locally advanced, unresectable NSCLC